Multiple Myeloma Scorecard: Efficacy, Cost, and Safety
New study compares published data from various treatment regimens for multiple myeloma, scoring them on efficacy, cost, and adverse effects.
New study compares published data from various treatment regimens for multiple myeloma, scoring them on efficacy, cost, and adverse effects.
The median total cost of hospitalization resulting from CAR-T treatment was found to be $380,052, with a median direct cost of $262,981.
Researchers have engineered CAR-T cells to express a peptide from scorpion venom to help them home to glioma cells.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
A new study describes how the flu vaccine creates an antitumoral response in mouse models of metastatic melanoma that has spread to the lungs.
A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model.
Research presented at SITC 2019 looks at 2 different mechanisms for resistance to immune checkpoint inhibition in pancreatic ductal adenocarcinoma.
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.